New LL-37-Derived Antimicrobial Peptide Shows Strong Activity Against Drug-Resistant Bacteria | Research

The takeaway

KF-22, a hybrid peptide derived from human LL-37 and snake cathelicidin fragments, showed potent antimicrobial activity against multidrug-resistant bacteria.

Potent MDR activity
Hybrid peptide KF-22 kills both Gram-positive and Gram-negative drug-resistant bacteria

What the researchers found

Hybrid peptide KF-22, fusing snake and human cathelicidin fragments, demonstrated potent activity against multidrug-resistant Gram-positive and Gram-negative bacteria.

Why it matters

Multidrug-resistant infections kill over a million people annually. Novel peptide antibiotics designed from natural AMP fragments offer new therapeutic options.

How the study worked

Rational peptide design by fragment fusion (Cathelicidin-BF 1-9 + LL-37 17-29), followed by antimicrobial activity testing against MDR bacterial panels.

What this study cannot tell us

In vitro testing only — in vivo efficacy, toxicity, and pharmacokinetics not yet established.

How to read the evidence

In vitro study — demonstrates antimicrobial potential but requires animal studies and safety testing before clinical consideration.

When this study was published

Published 2026 in European Journal of Medicinal Chemistry.

The bigger picture

Fragment-based AMP design, combining the best properties of peptides from different species, could accelerate development of the next generation of antibiotics.

Questions still open

Does KF-22 maintain activity in animal infection models?
Can the fragment-fusion approach be applied to create additional hybrid AMPs?

Common questions

What makes KF-22 special?

It combines the best parts of two natural antimicrobial peptides — one from snake venom and one from the human immune system — creating a hybrid that is more potent against drug-resistant bacteria than either source alone.

Can hybrid peptides replace antibiotics?

They have potential — antimicrobial peptides kill bacteria through different mechanisms than traditional antibiotics, making it harder for bacteria to develop resistance. But much more testing is needed before clinical use.

Read the original research

LL-37-derived peptide shows promising antimicrobial potential against multidrug-resistance pathogens.

European journal of medicinal chemistry, 304, 118547

View on PubMed ↗Publisher’s paper ↗

Citation

Asmamaw, Demeke; Cai, Huajun; Prateeksha, Prateeksha; Khalid, Mehwish; Mwangi, James; Yi, Wang; Lu, Quimin; Lai, Ren; Duan, Zilei. (2026). LL-37-derived peptide shows promising antimicrobial potential against multidrug-resistance pathogens.. European journal of medicinal chemistry, 304, 118547. https://doi.org/10.1016/j.ejmech.2025.118547